In one of the largest biotechnology deals of 2026, the UK’s GSK announced it will acquire Nuvalent, a US-based clinical-stage biotechnology company, for $10.6 billion in cash, gaining access to three promising lung cancer therapies.
GSK Nuvalent Acquisition will strengthen GSK’s position in precision oncology and expand its portfolio of targeted lung cancer treatments. The transaction gives GSK ownership of a portfolio focused on targeted cancer therapies designed to overcome resistance and side effects associated with current treatments.
According to an official announcement from GSK, the company will acquire all outstanding Nuvalent shares for $124 per share in cash, representing a significant premium over recent market prices.
“Today’s acquisition is a multi-product deal, consistent with our approach to acquire assets that have clinically proven targets and meaningfully address an efficacy and/or tolerability gap,” said Luke Miels, Chief Executive Officer of GSK.
The deal is expected to close following regulatory approvals and customary closing conditions.
How GSK’s Acquisition of Nuvalent Contributes To Lung Cancer
In Nuvalent’s takeover by GSK, the biotechnology company is focusing on precision medicine. Precision medicine uses a patient’s genetic profile to guide treatment decisions, allowing therapies to target specific cancer-driving mutations.
The Nuvalent acquisition includes a trio of lung cancer drugs consisting of:
- Zidesamtinib (NVL-520)
- Neladalkib (NVL-655)
- NVL-330
These therapies are designed to treat specific genetic forms of non-small cell lung cancer (NSCLC), the most common type of lung cancer.
Current treatments often face challenges such as:
- Drug resistance over time
- Limited effectiveness against brain metastases
- Significant side effects that affect quality of life
Nuvalent’s therapies aim to address these limitations through highly selective targeting of cancer-causing mutations.
Zidesamtinib and Neladalkib Lead the GSK Nuvalent Acquisition
Zidesamtinib Drug Targets ROS1-Positive Lung Cancer
Zidesamtinib is being developed for patients with ROS1-positive NSCLC, a rare form of lung cancer caused by alterations in the ROS1 gene.
The therapy has received both FDA Breakthrough Therapy Designation and Orphan Drug Designation. It is currently under U.S. Food and Drug Administration review, with a regulatory decision expected later in 2026.
Clinical data presented at major international lung cancer meetings have shown encouraging efficacy and safety results, supporting its potential as a best-in-class treatment.
Neladalkib Drug Focuses on ALK-Positive Disease
Neladalkib is designed for patients with ALK-positive NSCLC, another genetically driven subtype of lung cancer.
Like zidesamtinib, neladalkib has earned FDA Breakthrough Therapy and Orphan Drug designations. The treatment is also undergoing regulatory review and could become available to patients if approved later this year.
Researchers believe its ability to penetrate the blood-brain barrier may help address cancer spread to the brain, a common challenge in advanced lung cancer.
- Beyond the two late-stage candidates, the GSK Nuvalent acquisition includes NVL-330, an early-stage therapy targeting HER2-altered lung cancer.
By combining targeted therapies across multiple genetic mutations, GSK hopes to build a stronger position in one of the fastest-growing areas of cancer treatment.
Financial Impact of the GSK Nuvalent Takeover
The GSK Nuvalent acquisition is expected to contribute to revenue growth beginning in 2027. The British company stated that the transaction should become accretive to operating profit in 2027 and earnings per share by 2029, including anticipated synergies.
The company also reaffirmed its existing financial guidance and indicated that the acquisition supports its long-term ambition of achieving more than £40 billion in annual sales by 2031.
Importantly, GSK stated that the transaction will be funded through a combination of cash and debt facilities without affecting its investment-grade credit profile.
Conclusion
The GSK Nuvalent acquisition reflects a broader trend of major pharmaceutical companies investing heavily in targeted cancer treatments. As patent expirations approach across the industry, companies are increasingly pursuing innovative assets that can deliver future growth and improve patient outcomes.
In 2026, Pharma Giant Pfizer announced a collaboration with Innovent Biologics to develop next-gen cancer drugs. The weight-loss drug maker Eli Lilly has also acquired Kelonia Therapeutics to expand their portfolio in cancer.
If approved by regulators, zidesamtinib and neladalkib could launch later in 2026, giving GSK immediate entry into key segments of the lung cancer market. For patients living with genetically driven forms of NSCLC, the deal could ultimately expand access to more effective and potentially better-tolerated treatment options.
